Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14,202 | $13,117 | $12,173 | $16,072 |
| % Growth | 8.3% | 7.8% | -24.3% | – |
| Cost of Goods Sold | $1,971 | $2,245 | $1,705 | $2,724 |
| Gross Profit | $12,232 | $10,873 | $10,468 | $13,348 |
| % Margin | 86.1% | 82.9% | 86% | 83.1% |
| R&D Expenses | $5,233 | $3,987 | $3,056 | $2,622 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,954 | $2,540 | $2,116 | $1,825 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $53 | -$2 | -$90 | -$46 |
| Operating Expenses | $8,241 | $6,524 | $5,082 | $4,401 |
| Operating Income | $3,991 | $4,349 | $5,386 | $8,947 |
| % Margin | 28.1% | 33.2% | 44.2% | 55.7% |
| Other Income/Exp. Net | $789 | -$149 | -$527 | $379 |
| Pre-Tax Income | $4,780 | $4,199 | $4,859 | $9,326 |
| Tax Expense | $367 | $246 | $520 | $1,251 |
| Net Income | $4,413 | $3,954 | $4,338 | $8,075 |
| % Margin | 31.1% | 30.1% | 35.6% | 50.2% |
| EPS | 40.9 | 37.05 | 40.51 | 76.4 |
| % Growth | 10.4% | -8.5% | -47% | – |
| EPS Diluted | 38.34 | 34.77 | 38.22 | 71.97 |
| Weighted Avg Shares Out | 108 | 107 | 107 | 106 |
| Weighted Avg Shares Out Dil | 115 | 114 | 114 | 112 |
| Supplemental Information | – | – | – | – |
| Interest Income | $711 | $496 | $160 | $0 |
| Interest Expense | $55 | $73 | $59 | $57 |
| Depreciation & Amortization | $483 | $421 | $341 | $286 |
| EBITDA | $5,318 | $4,693 | $5,260 | $9,669 |
| % Margin | 37.4% | 35.8% | 43.2% | 60.2% |